Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Amortizatization of Intangibles (2023 - 2025)

Compass Therapeutics' Amortizatization of Intangibles history spans 3 years, with the latest figure at $353000.0 for Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles rose 61.19% year-over-year to $353000.0; the TTM value through Dec 2025 reached $1.2 million, up 2.75%, while the annual FY2025 figure was $1.2 million, 2.75% up from the prior year.
  • Amortizatization of Intangibles for Q4 2025 was $353000.0 at Compass Therapeutics, roughly flat from $352000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $353000.0 in Q4 2025 and bottomed at $219000.0 in Q4 2024.
  • The 3-year median for Amortizatization of Intangibles is $304500.0 (2023), against an average of $295916.7.
  • The largest annual shift saw Amortizatization of Intangibles dropped 28.66% in 2024 before it skyrocketed 61.19% in 2025.
  • A 3-year view of Amortizatization of Intangibles shows it stood at $307000.0 in 2023, then decreased by 28.66% to $219000.0 in 2024, then surged by 61.19% to $353000.0 in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Amortizatization of Intangibles are $353000.0 (Q4 2025), $352000.0 (Q3 2025), and $267000.0 (Q2 2025).